Valneva SE (VALN) Notes Payables (2020 - 2021)
Valneva SE's (VALN) quarterly Notes Payables came in at $8.1 million in Q4 2021, down 2.42% year-on-year from $8.3 million in Q4 2020, and down 2.42% quarter-over-quarter from $8.3 million in Q4 2020.
Valneva SE (VALN) Notes Payables (2020 - 2021) Analysis & Trends
Valneva SE has disclosed Notes Payables across 2 years of filings, most recently posting $8.1 million for Q4 2021.
- Notes Payables for Q4 2021 came in at $8.1 million, down 2.42% year-over-year; the trailing twelve-month figure through Dec 2021 was $8.1 million (down 2.42% YoY), and the FY2021 annual result was $8.4 million, up 5.41% from the prior year.
- Notes Payables came in at $8.1 million for Q4 2021 at Valneva SE, down from $8.3 million in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $8.3 million in Q4 2020 to a low of $8.1 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 8.13 Mn |
| Dec 31, 2020 | 8.33 Mn |